Business Wire

IMPROBABLE

24.7.2024 14:01:33 CEST | Business Wire | Press release

Share
Improbable Achieves Profitability in 2023 and Launches Its Venture Builder Model With a Strong Capital Position to Pursue New Investments

Highlights

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724891104/en/

  • Profitability achieved in 2023
    • Improbable submitted its filing to Companies House today. In 2023 the company achieved profitability, validating its technology and business.
    • Excluding one-time items, revenue increased by 37%, to a total of £66 million.
    • Improbable achieved profitability for the first time, recording £11 million in profit.
    • The company ended 2023 with a strong cash position of £185 million, driven by successful exits of its initial ventures.
    • The strategic focus on the metaverse early 2022 resulted in rightsizing of the company, generating increasing revenue and optimizing operations.
  • Technological edge and market position
    • A decade of investment and experience in high-performance distributed systems has positioned Improbable at the forefront of addressing scale in traditional cloud computing.
    • Additionally, having deployed its technologies throughout dozens of commercial applications, Improbable is leveraging this experience towards the development of emerging technologies for the metaverse, blockchain and AI.
    • The MSquared Platform now has many external content developers in early access mode and tens of metaverse projects are being regularly tested with consumers.
  • Successful shift to Venture Building in 2023
    • Improbable announced its transition to a venture builder model in Q3 2023, and triggered its first important exit with the sale of its games services business, MPG, at the end of the year.
    • The approach focuses on building ventures in cutting-edge sectors like AI, blockchain, and the metaverse, investing in both Infrastructure Ventures that serve as platforms for businesses and B2B or Consumer Application Ventures.
  • Support for ventures for a fast start
    • The company will deploy capital along with a broad set of support services, supporting founders with fundraising, strategic advice and simplified operations.
  • A hands-on approach for 2024-2025
    • Improbable aims to launch multiple start-ups annually, creating commercially successful businesses, and participating into a high value portfolio.
    • The company maintains equity in a valuable portfolio, contributing ideas and resources, and offering more operational involvement than typical funds or investors.

Herman Narula, Founder and Chief Executive Officer of Improbable declared: "A decade ago, we embarked on the challenging yet immensely rewarding journey of focusing on distributed systems for virtual worlds. Over this period, we have honed our expertise in bringing complex technology products to market, seeded and grown businesses, and developed proprietary technology with significant barriers to entry.

Two years ago, we doubled down on our commitment to the metaverse. In 2023, we recorded revenues of £66 million and achieved a total profit of £11 million, driven by growth, cost discipline, and divestment of high-value assets. We’ve uniquely demonstrated the ability to pursue distinct, real businesses simultaneously. Venture building has proven to be the optimal model for both Improbable and the metaverse, as experimenting with various use cases is key to achieving adoption.

Through strategic investments in both large partnerships and start-ups, we continue to advance the case for the metaverse. Our ambition is to shape the future, and our experience provides us with unique insights to do so. I extend my heartfelt thanks to our leadership team, especially our CFO, Dan Odell, for their unwavering dedication in propelling Improbable to its current place of strength."

Dan Odell, Chief Financial Officer: “Entering 2024, we have significantly improved our cost structure, and can count on a strong capital position further supported by the successful exits of our first ventures. Improbable has laid the foundation for executing on its Venture Builder strategy. The portfolio of ventures as we enter 2024 is exciting and I trust in the future success of the business.”

Peter Lipka, Chief Operating Officer: “We believe that there are significant unaddressed opportunities in the AI, web3 and metaverse sectors. We aim to identify founders that we can help accelerate by unlocking the capital they need, and providing a foundation for them to operate on. Our goal is for our venture builder model to be the best place to start a business in these sectors.”

Rob Whitehead, Chief Product Officer: “We are proud to continue hosting the highest density virtual events in the world. After primarily using this technology internally, we are thrilled to start opening our platform to external developers later this year, starting with Yuga Lab's Otherside Developer Kit (ODK). Our next steps involve enhancing this toolset, further developing interoperability on our network, advancing blockchain technology for metaverse applications, and exploring the transformative impact of Generative AI.”

Improbable is a start-up that has been at the forefront of building virtual worlds for over a decade.

We believe that the metaverse is an opportunity for communities, companies and brands to have a positive social and economic impact in the real world. Today, we are initiating new technologies, models and partnerships to venture further into new worlds.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724891104/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye